Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2015)
23 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 25, 2015
Slide 1: Phylogica 2015 Annual General Meeting
For personal use only Phylogica 2015 Annual General Meeting (PYC:ASX) Peptide therapeutics against intracellular oncology targets
Slide 2: Disclaimer
Disclaimer The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) For personal use only [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: Phylogica's exciting transformation
Phylogica’s exciting transformation: For personal use only From: A platform company using its proprietary Phylomer technology for drug discovery To: An cancer-‐focussed company developing first-‐in-‐ class intracellular therapies using its disruptive drug discovery engine AGM (25/11/2015) 3
Slide 4: 2015 Highlights
For personal use only 2015 Highlights § Completed $10m capital raise in July, 2015 § Validated ‘Best-‐in-‐Class’ Phylomers for delivering multiple drug classes inside cells § Major advances with in-‐house oncology pipeline: § Progress with commercialisation: – Genentech collaboration – First
Slide 5: Corporate Snapshot
For personal use only Corporate Snapshot Shareholders % Summary B. Hockings 28 ASX PYC Sietsma Holdings 9 Cash (Sep/15) $9.7m Swift 3 Net Burn $2.5m Top 15 56 Market Cap $34m Shares on issue 2,000m Executive Team Dr Richard Hopkins – CEO Dr P aul Watt -‐ CSO Board of Directors Bruce McHarrie Dr Dou
Slide 6: Core Technology
For personal use only Core Technology
Slide 7: Majority of drug targets (80%) are inside cells
Majority of drug targets (80%) are inside cells Intracellular Drug Targets For personal use only Small Molecule Drugs (10%) Biologics Undrugged targets (90%) (Smart drugs) § PYC addressing unmet need to deliver biologic drugs inside cells! AGM (25/11/2015) 7
Slide 8: PYC: specialists for intracellular delivery of biologics
PYC: specialists for intracellullar delivery of biologics For personal use only Potential to expand the druggable landscape by >10-‐fold!! AGM (25/11/2015) 8
Slide 9: The Problem: Drugs are unable to penetrate inside cells
For personal use only The Problem: Drugs are unable to penetrate inside cells Drug Drug Drug contacts cell membrane Endosome Drug contact triggers formation o f endosomes Cell Membrane Endosome Drug 99% of d rug trapped in endosomes Cell Membrane AGM (25/11/2015) 9
Slide 10: Superior cell penetrating Phylomers for delivering biologics drugs inside cells
Superior cell penetrating Phylomers for delivering biologics drugs inside cells For personal use only 159-‐fold 37-‐fold 50 40 Drug Deliver Efficiency R9 } Previous gold (% +ve Cells) 30 Standards TAT 20 Phylomer CPP 10 0 Cell penetrating peptide + biologics cargo § Phylomer CPPs: ‘Best in Class’
Slide 11: Phylomer CPPs: delivering new drug classes
For personal use only Phylomer CPPs: delivering new drug classes to expand the intracellular druggable landscape
Slide 12: MYC: A classic cancer target
MYC: A classic cancer target § MYC: Is ‘activated’ in most human cancers (>50%) -‐ recognised as a key driver of disease For personal use only Proliferation MYC Cell Growth Metabolism § Considered undruggable by conventional drugs. § Inhibiting MYC can eradicate existing tumours including lung,
Slide 13: Phylomer CPP-Omomyc fusions are potent!
Phylomer CPP-‐Omomyc fusions are potent! § Kills MYC-‐driven cancer cell lines with unprecedented potencies For personal use only § Improves efficacy of other cancer drugs up to 10X. § First to show CPP-‐Omomyc fusion can significantly reduce tumor size in an animal model of breast cancer. §
Slide 14: Phylogica's Proprietary Cancer Pipeline
For personal use only Phylogica’s Proprietary Cancer Pipeline
Slide 15: Phylogica's Intracellular Oncology Pipeline
Phylogica’s Intracellular Oncology Pipeline § Phylomer screens against validated and clinically relevant oncology targets For personal use only § Validated hits already exceed potency of gold standard therapies ✔ ✔ Program Target Indications Discovery Hit to Lead Validation Preclinical In vitro In
Slide 16: Key phases to clinical development
For personal use only Key phases to clinical development Hit Identification Hit to Lead Lead Candidates Lead Candidate (3 Targets) (1-‐2 Targets) (1-‐2) Discovery Animal Models of Cancer Lead Optimisation Preclinical/IND 2015 2016 2017 AGM (25/11/2015) 16
Slide 17: Focus on Leukaemia/Lymphoma
Focus on Leukaemia/Lymphoma § Unmet clinical need -‐ commercial opportunity For personal use only – Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia, Multiple Myeloma – Niche opportunities exist to control disease in patients awaiting transplant § Standard method of treatment is IV infusion, §
Slide 18: Preclinical phase opens key commercial opportunities
For personal use only Preclinical phase opens key commercial opportunities
Slide 19: Major trend towards Preclinical and Phase licensing
Major trend towards Preclinical and Phase 1 licensing Stage of oncology licensing deals For personal use only (Av. number of deals as %) 74 78 Marketed 29% 44% Registration 1% 10% Phase III 3% 10% 23% Phase II 26% 11% Phase I 7% 25% Pre-‐clinical 10% 2008-‐2013 2008-‐13 2014 2014 AGM (25/11/2015)
Slide 20: Essential requirements for preclinical deals
For personal use only Essential requirements for preclinical deals Feature PYC Platform to address unique target landscape and unmet medical need. ✔ Strong IP barriers and FTO ✔ Well supported biological rationale for target ✔ Differentiated product/disruptive technology – ‘first-‐in-‐class’ thera
Slide 21: Summary
Summary § Advancing proprietary pipeline focused on blood cancers For personal use only § Developing ‘first and best-‐in-‐class’ therapies against challenging intracellular cancer targets § Disruptive Phylomer engine for drug discovery and drug delivery § Strategically positioned to realise co
Slide 22: Thankyou!
For personal use only Thankyou! AGM (25/11/2015) 22
Slide 23: Contact Details
Dr. Richard Hopkins Contact Details Dr. Paul Watt Chief Executive Officer Chief Scientific Officer Tel: +61 8 9489 7777 Tel: +61 8 9489 7777 Fax: +61 8 9489 7700 For personal use only Fax: +61 8 9489 7700 Mobile: +61 405 656 868 Mobile: +61 421 550 213 richardh@phylogica.com paulw@phylogica.com www.